Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure

AIMS: Heart failure (HF) is a common co‐morbidity in non‐valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time‐in‐therapeutic range with warfarin. We assessed the real‐world effectiveness and safety of rivaroxaban and warfarin in NVAF patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Brandon K., Bunz, Thomas J., Eriksson, Daniel, Meinecke, Anna‐Katharina, Sood, Nitesh A., Coleman, Craig I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352884/
https://www.ncbi.nlm.nih.gov/pubmed/30299591
http://dx.doi.org/10.1002/ehf2.12365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352884/
https://www.ncbi.nlm.nih.gov/pubmed/30299591
http://dx.doi.org/10.1002/ehf2.12365

Ejemplares similares